Immunic, Inc. (NASDAQ:IMUX) Q4 2022 Earnings Call Transcript

Page 5 of 5

Daniel Vitt: Thanks, Jessica, and thank you to today’s attendees for your insightful questions. To summarize, we very much look forward to reporting clinical data from our vidofludimus calcium and IMU-856 programs this year. Data from the Part C portion of our Phase I clinical trial of IMU-856 in celiac disease patients is expected to be available midyear. Moreover, we expect to report data from the interim analysis of our Phase II CALLIPER trial of vidofludimus calcium in progressive MS in the second half of this year. We remain well funded with $116.4 million on our balance sheet providing us runway through multiple clinical milestones into the fourth quarter of 2024. With that, I would like to close today’s call. Again thank you very much for joining and we are very happy to answer any additional questions one-on-one.

Jessica Breu: Thank you for joining Immunic’s year end 2022 earnings call. The webcast has now concluded. You may now disconnect.

Follow Immunic Inc. (NASDAQ:IMUX)

Page 5 of 5